A recent retrospective study led by Dr. Marilyn J. Siegel and her team at the Washington University School of Medicine in St. Louis has shed light on a critical issue in cancer care: routine clinical reads are more prone to overdiagnosing progressive disease when compared to RECIST 1.1 interpretations. This discrepancy holds significant implications, potentially leading to the premature discontinuation of effective treatments for cancer clinical trial participants and patients under standard care.
In this study, mint Lesion software was utilized for the criteria-based reads, determining overall response assessments according to RECIST 1.1 criteria, and generating structured reports for the clinical trial's principal investigator.
To learn more about the study's insights into the discrepant assessments and the suggested steps for mitigating this issue, click here.
Study Discovers Overdiagnosis of Progressive Cancer in Routine Clinical Evaluations
Related Resources
Related Resources
Radiologist’s AI-powered workflow
We all have been exposed to the riveting news of artificial intelligence tools taking over diagnostic imaging. Due to the rapid increase in global…
Mint Medical and Agfa HealthCare announce seamless integration of mint Lesion and ORBIS RIS at RSNA 2018
Heidelberg, Bonn, GER - At this year’s Radiological Society of North America (RSNA) Annual Meeting 2018, Agfa HealthCare and Mint Medical will…
mint PI-RADS V2 report as the standard for communication with urologists - Interview with PD Dr. Röthke
Since the beginning of 2017, all PI-RADS v2 reads are exclusively performed with mint Lesion™ by PD Dr. Matthias Röthke, Chief Medical Officer at…